Roche's lung cancer combo treatment wins FDA approval
Swiss drugmaker Roche Holding AG said on Thursday that its Tecentriq immunotherapy in combination with chemotherapy was approved by the U.S. Food and Drug Administration as a first-line treatment for a form of lung cancer.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Food and Drug Administration (FDA) | Health | Immunotherapy | Lung Cancer | Switzerland Health